© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
October 13, 2020
The FDA granted approval for Pralsetinib as well as a companion diagnostic to test for RET fusions.
September 21, 2020
Patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin had increased overall survival at 12- and 18-month intervals.
Two recent studies indicate oncological outcomes were not affected by delayed radical prostatectomy, supporting current recommendations for management of intermediate- and high-risk patients with prostate cancer during the COVID-19 pandemic.
June 22, 2020
Study presented at the AACR Virtual Annual Meeting II supports an increased role for genetic testing in these patients.